The pathophysiology of fibrocystic breast disease is determined by estrogen predominance and progesterone deficiency that result in hyperproliferation of connective tissue fibrosis , which is followed by facultative epithelial proliferation; the risk of breast cancer is increased twofold to fourfold in these patients. The clinical correlate of fibrocystic disease is reflected by breast and axillary pain or tenderness in response to development of fibrocystic plaques, nodularity, macrocysts, and fibrocystic lumps. The disease progresses with advancing premenopausal age and is most pronounced in women during their 40s. Fibrocystic changes regress during the postmenopausal period.
Benign breast disease and the risk of breast cancer in the next 15 years
These changes are sometimes called fibrocystic changes , and used to be called fibrocystic disease. Areas of fibrosis feel rubbery, firm, or hard to the touch. They are often felt as a round, movable lump, which might also be tender to the touch. Cysts begin when fluid starts to build up inside the breast glands. These can be felt easily and can be as large as 1 or 2 inches across. Simple cysts are not usually a cause for concern.
This material must not be used for commercial purposes, or in any hospital or medical facility. Failure to comply may result in legal action. Medically reviewed by Drugs. Last updated on Nov 16, Fibrocystic changes are changes in your breast tissue.
What Are Fibrocystic Breasts? The most common signs of fibrocystic breasts include lumpiness, tenderness, cysts packets of fluid , areas of thickening, fibrosis scar-like connective tissue , and breast pain. Having fibrocystic breasts, in and of itself, is not a risk factor for breast cancer.